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Abstract A number of reports have identified phosphatidylino-
sitol 3-kinase as a downstream effector of Ras in various cellular
settings, in contrast to others supporting the notion that
phosphatidylinositol 3-kinase acts upstream of Ras. Here, we
used Xenopus oocytes, a model of Ras-mediated cell cycle
progression (G2/M transition) to analyze the contribution of
phosphatidylinositol 3-kinase to insulin/Ras-dependent signaling
pathways leading to germinal vesicle breakdown and to ascertain
whether phosphatidylinositol 3-kinase acts upstream or down-
stream of Ras in those signaling pathways. We analyzed the
process of meiotic maturation induced by progesterone, insulin or
micro-injected oncogenic Ras (Lys12) proteins in the presence
and absence of specific inhibitors of phosphatidylinositol 3-kinase
activity. As expected, the progesterone-induced maturation was
independent of phosphatidylinositol 3-kinase since similar rates
of germinal vesicle breakdown were produced by the hormone in
the presence and absence of wortmannin and LY294002. In
contrast, insulin-induced germinal vesicle breakdown was com-
pletely blocked by pre-incubation with the inhibitors prior to
insulin treatment. Interestingly, similar rates of germinal vesicle
breakdown were obtained in Ras (Lys12)-injected oocytes,
independently of whether or not they had been pre-treated with
phosphatidylinositol 3-kinase inhibitors. The effect of wortman-
nin or LY294002 on MAPK and Akt activation by progesterone,
insulin or Ras was also analyzed. Whereas insulin activated those
kinases in a phosphatidylinositol 3-kinase-dependent manner,
progesterone and Ras were able to activate those kinases in the
absence of phosphatidylinositol 3-kinase activity. Since Ras is a
necessary and sufficient downstream component of insulin
signaling pathways leading to germinal vesicle breakdown, these
observations demonstrate that phosphatidylinositol 3-kinase is
not a downstream effector of Ras in insulin/Ras-dependent
signaling pathways leading to entry into the M phase in Xenopus
oocytes.
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1. Introduction
Fully grown (stage VI) Xenopus oocytes are physiologically
arrested at the G2 stage of the ¢rst meiotic prophase. Physio-
logical doses of progesterone and pharmacological doses of
insulin are able to break the blockade and induce entry into
the M phase triggering germinal vesicle breakdown (GVBD)
through activation of a variety of signaling pathways (re-
viewed in [1^3]). Thus, progesterone leads to a decreased ad-
enylate cyclase activity, with a resulting drop in overall cAMP
levels and the subsequent cascade of protein kinase A (PKA)-
dependent phosphorylations. In contrast, insulin or IGF-1
triggers a cascade of phosphorylations initiated by the speci¢c
receptor tyrosine kinase (RTK). Both progesterone and insu-
lin-initiated pathways eventually converge into the ¢nal acti-
vation of the MPF kinase complex, a universal activator of M
phase transition in eukaryotic cells and an absolute require-
ment for GVBD [4,5]. MAPK activation appears to be a
necessary and su⁄cient step in the process of GVBD induc-
tion [6^10].
Ras and other oncogenic proteins have also been shown to
induce meiotic maturation when micro-injected into Xenopus
oocytes [11^17]. Several lines of evidence indicate that Ras
proteins are essential components in pathways of insulin-in-
duced maturation, but not in progesterone-induced GVBD
[18^20].
Because the progesterone (PKA-dependent) and insulin/Ras
(RTK-dependent) signaling cascades are already partially
characterized, injection of putative signaling intermediates
into Xenopus oocytes is a valuable tool to analyze their po-
tential contribution in signaling pathways controlling cell pro-
liferation. Thus, the Xenopus system has been succesfully used
to analyze the functional contribution of a variety of isolated,
puri¢ed modular domains present in proteins involved in the
regulation of RTK/Ras signaling pathways and/or cell cycle
progression [21^28]. These reports demonstrate that Xenopus
oocytes constitute a useful biological model system to func-
tionally analyze components of RTK/Ras signaling pathways.
Phosphatidylinositol 3-kinases (PI3K) are a family of evo-
lutionarily conserved enzymes capable of phosphorylating
phosphoinositides at the 3P position of the inositol ring. The
common heterodimeric PI3K isoforms are composed of a cat-
alytic subunit (p110) and a regulatory subunit (p85). Activa-
tion of the p85-p110 PI3K complex, through a variety of
molecular mechanisms, is known to play essential roles in
signal transduction processes related to a variety of cellular
activities such as cytoskeletal re-arrangement, cellular migra-
tion, di¡erentiation, protection from apoptosis and mitogen-
esis (reviewed in [29^32]).
PI3Ks are recognized as essential components of receptor
tyrosine kinase-activated signaling pathways, such as those
initiated by PDGF and insulin, in mammalian cells [33^35].
However, analysis of the participation of PI3K in RTK/Ras
signaling pathways has yielded apparently con£icting reports.
Thus, whereas some reports have identi¢ed Ras as a down-
stream target in various cellular settings [36^38], others clearly
place PI3K upstream of Ras and/or MAPK [39^42].
A number of reports have described the participation of
PI3K [21,27,43^45], its distal kinase Akt [46] and the signaling
inositol phosphatase SIP/SHIP [47] in the process of insulin-
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 5 9 5 - 5
*Corresponding author. Fax: (1) (301) 496 8479.
E-mail: santos@helix.nih.gov
FEBS 22055 25-5-99
FEBS 22055FEBS Letters 451 (1999) 284^288
induced GVBD in oocytes. PI3K has also been reported to
participate in the regulation of glucose transport in the oo-
cytes [48,49]. In view of the con£icting reports in mammalian
cells, we decided to utilize the model system of cell cycle pro-
gression in Xenopus oocytes to ask whether Ras participates
upstream or downstream of PI3K in the signaling pathways
leading to cell cycle progression into the M phase. Our exper-
imental approach involved micro-injection of activated Ras
oncoproteins and subsequent analysis of the resulting process
of meiotic maturation under basal, native conditions or under
conditions where the endogenous PI3K activity was blocked
by speci¢c inhibitors.
2. Materials and methods
2.1. p21Ras protein puri¢cation
Transforming H-Ras (Lys12) protein was expressed in Escherichia
coli and puri¢ed from the insoluble fraction by extraction with urea,
as previously described [17,26,27].
2.2. Oocyte preparation, micro-injection and maturation
Adult female Xenopus laevis were obtained from Nasco (Fort At-
kinson, WI, USA), Xenopus I (Ann Arbor, MI, USA) and Carolina
Biological Supply (Burlington, NC, USA) and stimulated to ovulate
by injecting 50 U of pregnant mare serum gonadotropin (Calbiochem,
San Diego, CA, USA, 367222) several days prior to oocyte extraction.
Ovarian fragments were surgically removed from frogs anesthetized
by hypothermia. Fully grown stage VI oocytes were manually dis-
sected into ND-96 medium (5 mM HEPES, 96 mM NaCl, 1 mM
MgCl2, 2 mM KCl, 1.8 mM CaCl2, pH 7.8 and 10 Wg/ml each of
penicillin and streptomycin sulfate). The oocytes were allowed to re-
cover overnight in the same bu¡er before further treatment and were
always maintained at 20‡C. For induction of meiotic maturation,
groups of 10^30 oocytes were incubated in ND-96 without KCl in
the presence of insulin (7.5 WM, Sigma), progesterone (15 WM, Sigma)
or were micro-injected into the cytoplasm with 5 ng p21Ras (Lys12)
(60 nl, in 20 mM Tris, pH 7.5). Controls were micro-injected with
bu¡er alone. When needed, wortmannin (100 nM, Sigma) [50],
LY294002 (30 WM, Calbiochem) [51], PD98059 (50 WM, New England
Biolabs) [52] or BAPTA-AM (20 WM, Molecular Probes) [53] were
added to the medium at least 1 h before micro-injection of p21Ras or
exposure to hormones. Wortmannin or BAPTA-AM were added to
the medium and washed away after 30 min. LY294002 or PD98059
were maintained in the medium during the course of the experiment.
Meiotic maturation was assayed by scoring the disappearance of
the nucleus (GVBD) in oocytes ¢xed with 10% trichloroacetic acid. In
most cases, the absence of the nucleus correlated with the appearance
of a white spot in the animal pole.
2.3. Protein kinase assays
Clari¢ed extracts were utilized for the di¡erent kinase assays. For
preparation of the extracts, speci¢c groups of oocytes were homogen-
ized in ice-cold bu¡er (20 Wl per oocyte) containing 50 mM Tris pH
7.5, 50 mM L-glycerophosphate, 50 mM NaCl, 15 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, 0.5% NP-40, 7 mM NaF, 1 mM Na3VO4,
1 mM dithiothreitol, 1 mM phenylmethylsulfonyl£uoride and 10 Wg/
ml each of aprotinin and leupeptin. Assays of kinase activity on spe-
ci¢c substrates (myelin basic protein (MBP), histone H2) were per-
formed directly in cytosolic extracts or in immunocomplexes, as de-
scribed below. To ensure speci¢city, protein kinase A inhibitor was
always present in the reaction mixtures.
For MAPK activity determination, MBP kinase assays were per-
formed as described [17] using 1.5 mg/ml of MBP (Sigma) as substrate
in a bu¡er containing 20 mM Tris pH 7.5, 100 mM L-glycerophos-
phate, 15 mM MgCl2, 10 mM EGTA, 1 mM DTT, 1 mM PMSF,
1 mM Na3VO4, 20 WM cold ATP, 1 WCi [Q-32P]ATP, with protein
kinase A inhibitor peptide (7 WM, Gibco BRL). 5 Wl of oocyte extracts
was incubated with 25 Wl of the reaction bu¡er at 30‡C for 20 min.
Radioactivity in the MBP band was visualized by autoradiography
after SDS-PAGE on 10^20% polyacrylamide gradient minigels.
For Akt activity determination, histone H2 kinase assays [54] were
performed on immune complexes resulting from 90 Wl of clari¢ed
extracts incubated with 400 ng anti-Akt antibodies (Santa Cruz SC-
1618) and protein G agarose beads for 2^3 h at 4‡C. Immunopreci-
pitates were washed twice with lysis bu¡er, twice with a bu¡er con-
taining 0.5 M LiCl, 100 mM Tris-HCl, 1 mM EDTA, pH 8.0, and
once with kinase bu¡er. The kinase reaction was carried out with 25 Wl
of the kinase bu¡er containing 2.5 Wg H2B, 5 WM cold ATP, 7 WM
protein kinase A inhibitor and 10 WCi [Q-32P]ATP. Radioactivity in the
histone H2B band was visualized by autoradiography after SDS-
PAGE on 10^20% polyacrylamide gradient minigels.
3. Results
3.1. The e¡ect of PI3K inhibitors on induction of GBVD by
progesterone, insulin and micro-injected Ras (Lys12)
protein
We ¢rst analyzed the kinetics of GVBD induced by proges-
terone, insulin or micro-injected Ras, in the presence and
absence of wortmannin and LY294002, two speci¢c inhibitors
of PI3K activity [50,51]. Separate groups of oocytes were in-
cubated with the PI3K inhibitors (or DMSO in the case of
untreated, control oocytes) and then treated with either pro-
gesterone or insulin or micro-injected into the cytoplasm with
puri¢ed, bacterially expressed p21Ras (Lys12) [17,26,27]. As
additional controls, separate sets of insulin-induced or Ras-
injected oocytes were treated with the MEK inhibitor
Fig. 1. The e¡ect of PI3K inhibitors on Xenopus oocyte GVBD in-
duced by insulin, progesterone or micro-injected, oncogenic Ras
(Lys12) proteins. Separate groups of oocytes, maintained in ND-96
medium, were incubated in ND-96 medium after addition of hor-
mones or micro-injection of Ras proteins, as indicated. When
needed, wortmannin, LY294002 and PD98059 were added to the
medium 1 h prior to incubation with hormones or micro-injection.
Bars represent the percentage of GVBD measured after 16 h under
the di¡erent conditions. Similar results were obtained in three sepa-
rate experiments. C, untreated oocytes. P, oocytes treated with
15 WM progesterone. P+W, oocytes pretreatment with wortmannin
and incubation in the presence of progesterone. P+LY, oocytes pre-
treated with LY294002 and incubated with progesterone. I, incuba-
tion in the presence of 7.5 WM insulin. I+W, oocytes pretreatment
with wortmannin and incubation in the presence of insulin. I+LY,
oocytes pre-treated with LY294002 and incubated with insulin.
I+PD, pretreatment with PD98059 and incubation with insulin.
Ras, oocytes injected with 5 ng each of puri¢ed Ras (Lys12) protein
and incubated in regular medium. Ras+W, pretreatment with wort-
mannin prior to Ras injection. Ras+LY, oocytes pre-treated with
LY294002 prior to Ras injection. Ras+PD, pretreatment with
PD98059 prior to Ras injection.
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PD98059 [52] to demonstrate the dependence of GVBD on
MAPK activation (Fig. 1).
We observed that progesterone-induced maturation was in-
dependent of PI3K activity, since similar rates of GVBD were
produced by the hormone in the presence and absence of
wortmannin or LY294002 (Fig. 1). In contrast, and consistent
with a previous report [44], insulin-induced GVBD was com-
pletely blocked by pre-incubation with the PI3K inhibitors
prior to insulin treatment. Interestingly, similar rates of
GVBD were obtained in Ras (Lys12)-injected oocytes, inde-
pendently of whether or not they were pre-treated with wort-
mannin or LY294002 (Fig. 1).
Ras proteins have been shown to be essential signaling in-
termediates in insulin signaling pathways leading to GVBD,
but not in progesterone-induced GVBD [18^20]. Therefore,
our observations are not consistent with PI3K acting as a
downstream e¡ector of Ras in the oocytes, but rather suggest
that PI3K acts upstream of Ras or, in a parallel signaling
pathway, in the process of insulin/Ras-induced GVBD.
3.2. The e¡ect of PI3K inhibitors on MAPK activation
Previous studies have indicated that MAPK activation is a
necessary and su⁄cient step in the processes of GVBD induc-
tion by the hormones progesterone and insulin and by micro-
injected Ras proteins [6^10,17].
Here, we measured MAP kinase activity (using MBP as a
substrate) in total cell lysates of oocytes after stimulation with
the hormones or micro-injection with Ras proteins, in the
presence and absence of wortmannin or LY294002 (Fig. 2).
In agreement with previous reports [7,8,17], autoradiographic
estimation of the MBP kinase activity in comparison to un-
treated controls con¢rmed that the MAPK activity was sig-
ni¢cantly activated in oocytes shortly after treatment with
either progesterone or insulin or micro-injection with the ac-
tivated Ras (Lys12) oncoprotein. This activation was speci¢-
cally blocked by the MEK inhibitor PD98059 (Fig. 2). In
contrast, pretreatment of the oocytes with PI3K inhibitors
prior to hormone treatment or Ras micro-injection showed
a di¡erent pattern of responses in MAPK activation. Thus,
whereas insulin-induced activation of MAPK was completely
blocked by pretreatment with wortmannin or LY294002, the
activation of MAPK by progesterone or micro-injected Ras
was completely una¡ected by the same treatment with the
PI3K inhibiting drugs (Fig. 2). These observations with
MAPK activation completely parallel the behavior observed
in the measurements of the kinetics of GVBD under similar
experimental conditions (Fig. 1).
MAPK activation appears to be a prerequisite for GVBD
and MPF activation induced by hormones or micro-injected
Ras proteins [6^10,17]. Our present observations clearly indi-
cate that only insulin requires contribution of PI3K for acti-
vation of MAPK, whereas progesterone and oncogenic Ras
were able to activate MAPK without the contribution of the
activity of PI3K. Since both Ras [18^20] and PI3K ([44], our
observations) have been shown to be downstream signaling
elements of insulin-initiated signaling pathways leading to
GVBD, it follows that PI3K cannot be a downstream e¡ector
of Ras in the signaling pathways leading to cell cycle progres-
sion and entry into the M phase in Xenopus oocytes.
3.3. The e¡ect of PI3K inhibitors on Akt kinase activity
Akt, or protein kinase B, has been identi¢ed as a serine/
threonine kinase acting distally to PI3K in pathways regulat-
ing mammalian cell di¡erentiation and survival (reviewed in
[30]). A recent report has shown that Akt overexpression in
Xenopus oocytes resulted in GVBD through a process involv-
ing downstream activation of type 3 phosphodiesterase PDE3
[46].
In order to further characterize the role of PI3K signaling
in Ras-induced GVBD, we measured the Akt activity present
in di¡erent sets of wortmannin- or LY294002-treated and un-
Fig. 2. The e¡ect of PI3K inhibitors on MAPK activation by insu-
lin, progesterone or micro-injected, oncogenic Ras (Lys12) proteins
in Xenopus oocytes. MAPK activity was estimated in the oocytes by
performing in vitro MBP kinase assays in cleared lysates (5 Wl)
from oocytes treated under the same conditions as in Fig. 1. Radio-
activity incorporated in the MBP band was visualized by autora-
diography. The upper panel shows similar amounts of MAPK pro-
tein in all samples assayed. I, treatment with 7.5 WM insulin for
16 h. I+W, pretreatment with wortmannin prior to insulin treat-
ment. I+LY, pretreatment with LY294002 prior to insulin treat-
ment. I+PD, pretreatment with PD98059 prior to insulin treatment.
Ras, injection of 5 ng Ras (Lys12). Ras+W, pretreament with wort-
mannin prior to Ras injection. Ras+LY, pretreatment with
LY294002 prior to Ras injection. Ras+PD, pretreatment with
PD98059 prior to Ras injection. C, control oocytes. P, 15 WM pro-
gesterone. P+W, pretreatment with wortmannin prior to progester-
one treatment.
Fig. 3. The e¡ect of PI3K inhibitors on Akt activation by insulin,
progesterone or micro-injected, oncogenic Ras (Lys12) proteins in
Xenopus oocytes. Akt activity was estimated by performing in vitro
histone 2B kinase assays in speci¢c anti-Akt immunoprecipitates
from oocyte-cleared lysates. Radioactivity incorporated into histone
2B (H2B) was visualized by autoradiography. The upper panel
shows the presence of equal amounts of Akt protein in all samples
assayed. I, treatment with 7.5 WM insulin for 16 h. I+W, pretreat-
ment with wortmannin prior to insulin treatment. I+LY, pretreat-
ment with LY294002 prior to insulin treatment. I+PD, pretreatment
with PD98059 prior to insulin treatment. I+BAPTA, pretreatment
with BAPTA-AM prior to insulin treatment. Ras, injection of 5 ng
Ras (Lys12). Ras+W, pretreament with wortmannin prior to Ras
injection. Ras+LY, pretreatment with LY294002 prior to Ras injec-
tion. Ras+PD, pretreatment with PD98059 prior to Ras injection.
Ras+BAPTA, pretreatment with BAPTA-AM prior to Ras injec-
tion. C, control oocytes. P, 15 WM progesterone. P+W, pretreatment
with wortmannin prior to progesterone treatment.
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treated oocytes that were also treated with progesterone or
insulin or micro-injected with oncogenic Ras. In vitro Akt
kinase assays were performed, using histone 2B as a substrate
[54], on immunoprecipitates of oocyte lysates obtained using
speci¢c anti-Akt antibodies (Santa Cruz). Fig. 3 shows the
pattern of Akt activity detected under various sets of condi-
tions in the same groups of oocytes assayed for MAPK ac-
tivity in the previous ¢gure. Insulin treatment resulted in a
signi¢cant activation of Akt activity in the oocytes and this
activation was totally dependent on PI3K since pre-incubation
with wortmannin or LY294002 completely blocked Akt acti-
vation by insulin. Progesterone or micro-injected Ras also
induced activation of Akt in the oocytes (Fig. 3). However,
in those cases, prior inactivation of PI3K by pre-incubation
with PI3K inhibitors did not a¡ect signi¢cantly the level of
Akt activation achieved (Fig. 3). The process of Akt activa-
tion by insulin or micro-injected Ras was further probed in
the presence of the speci¢c MEK inhibitor PD98059 or the
Ca2 chelator BAPTA-AM. Neither of these reagents altered
the pattern of Akt activation observed with insulin or Ras
oncogenes alone (Fig. 3).
These observations further support the notion that Ras
proteins are not upstream activators of PI3K in the process
of GVBD in oocytes. In addition, they also indicate that Ras
proteins are able to induce activation of Akt without the
contribution of PI3K or the MEK/MAPK cascade. In sum-
mary, our ¢ndings underscore the notion that Akt may be
activated in oocytes through PI3K-dependent and -independ-
ent pathways, as has also been reported in mammalian cells
[32,55,56].
4. Discussion
Xenopus oocytes provide a valuable system for dissecting
insulin-induced signaling pathways and ascertaining the con-
tribution of Ras and PI3K to those pathways. Ras proteins
have been previously shown to be necessary and su⁄cient for
insulin-induced GVBD [11,18^20], with the MAPK cascade
lying downstream of Ras in the signaling pathway leading
to activation of MPF, the p34/cdc2 kinase complex whose
activation is an essential requirement for entry into the M
phase [4^8,10,17]. PI3K has been shown to be an essential
component of insulin-induced GVBD signaling since treat-
ment with wortmannin or micro-injection of isolated SH2
domains blocked the process [21,27,43,44]. However, the func-
tional relationship between Ras and PI3K in oocytes has not
been fully resolved yet. Questions remain about the potential
participation of PI3K and Ras in common or separate signal-
ing cascades initiated by insulin. More importantly, when
PI3K and Ras act in the same pathway, it is important to
determine whether PI3K functions as a downstream e¡ector
of Ras or as an upstream element of their shared signaling
pathway.
In this report, we showed that, in contrast to insulin, micro-
injected Ras (Lys12) proteins and progesterone were able to
induce GVBD in oocytes under conditions where the endog-
enous PI3K activity was completely inhibited by pretreatment
with speci¢c inhibitors [50,51]. In further contrast with insu-
lin, micro-injected Ras proteins and progesterone were able to
activate downstream kinases such as MAPK and Akt during
the process of GVBD induction in the presence of wortman-
nin or LY294002. Since PI3K and Ras proteins are clearly
necessary and su⁄cient downstream elements of insulin-initi-
ated signaling pathways [18^21,27,43,44], our observations
demonstrate that PI3K cannot be a downstream e¡ector of
Ras in the insulin signaling pathway. Our observations also
strongly suggest that the observed activation of Akt by Ras
and progesterone in wortmannin- or LY294002-treated oo-
cytes is PI3K-independent. Since wortmannin is an irreversi-
ble inhibitor of PI3K [50] and no new protein synthesis occurs
during oocyte GVBD after 2 h of hormonal stimulation
[57,58], it is highly unlikely that late PI3K-generated lipids
are responsible for the observed activation of Akt.
Our results cannot formally discern whether PI3K acts up-
stream of Ras or in a separate, parallel pathway. However,
the observation that oocyte maturation induced by a consti-
tutively active mutant of PI3K is inhibited by dominant neg-
ative Ras [39] strongly indicates that PI3K and Ras act in the
same signaling cascade. We conclude (Fig. 4) that PI3K acts
upstream of Ras in the insulin-induced signaling cascade trig-
gering GVBD and entry into the M phase in oocytes. Our
observations also indicate that Ras can activate Akt in a
MEK/MAPK- and PI3K-independent fashion.
Acknowledgements: E.L.H. was the recipient of a NATO postdoctoral
fellowship.
References
[1] Grigorescu, F., Baccara, M.T., Rouard, M. and Renard, E.
(1994) Horm. Res. 42, 55^61.
Fig. 4. Di¡erential contribution of PI3K and Ras to insulin-induced
GVBD. Schematic model depicting functional interactions among
PI3K, Ras, MAPK and Akt in insulin-induced signaling pathways
initiated by its speci¢c surface receptor (IR) and leading to GVBD
in oocytes. MAPK activation occurs downstream of Ras and is an
essential requirement for MPF activation and GVBD [6^10,17]. In-
jection of an activated Akt has been reported to induce GVBD in
oocytes [46]. The observations presented in this report, together
with previously published reports [18^20,39,44], indicate that PI3K
acts upstream of the endogenous, normal Ras in insulin induction
of GVBD. Because PI3K is not a downstream e¡ector of Ras in oo-
cytes, exogenously injected, oncogenic Ras (Lys12) proteins are able
to induce activation of MAPK and MPF in the absence of PI3K
activation by insulin. The results also indicate that Akt can be acti-
vated in a PI3K-dependent and -independent fashion.
FEBS 22055 25-5-99
E. Lo¤pez-Herna¤ndez, E. Santos/FEBS Letters 451 (1999) 284^288 287
[2] King, R.W., Jackson, P.K. and Kirschner, M.W. (1994) Cell 79,
563^571.
[3] Maller, J.L. (1994) Semin. Dev. Biol. 5, 183^190.
[4] Nurse, P. (1990) Nature 344, 503^508.
[5] Pines, J. and Hunter, T. (1990) New Biol. 2, 389^401.
[6] Kosako, H., Gotoh, Y. and Nishida, E. (1994) EMBO J. 13,
2131^2138.
[7] Fukuda, M., Gotoh, Y., Kosako, H., Hattori, S. and Nishida, E.
(1994) J. Biol. Chem. 269, 33097^33101.
[8] Gotoh, Y., Masuyama, N., Dell, K., Shirakabe, K. and Nishida,
E. (1995) J. Biol. Chem. 270, 25898^25904.
[9] Huang, W., Kessler, D.S. and Erickson, R.L. (1995) Mol. Biol.
Cell 6, 237^245.
[10] Haccard, O., Lewellyn, A., Hartley, R.S., Erickson, E. and Mal-
ler, J.L. (1995) Dev. Biol. 168, 677^682.
[11] Birchmeier, C., Broeck, D. and Wigler, M. (1985) Cell 43, 615^
621.
[12] Sagata, N., Oskarsson, M., Copeland, T., Brumbaugh, J. and
Vande Woude, G.F. (1988) Nature 335, 519^526.
[13] Daar, I.O., White, G.A., Schuh, S.M., Ferris, D.K. and Vande
Woude, G.F. (1991) Mol. Cell. Biol. 11, 5985^5991.
[14] Nebreda, A.R., Martin-Zanca, D., Kaplan, D., Parada, L.F. and
Santos, E. (1991) Science 252, 558^561.
[15] Graziani, G., Nebreda, A.R., Srivastava, S.K., Santos, E. and
Eva, S. (1992) Oncogene 7, 229^235.
[16] Fabian, J.R., Morrison, D.K. and Daar, I.O. (1993) J. Cell Biol.
122, 645^652.
[17] Nebreda, A.R., Porras, A. and Santos, E. (1993) Oncogene 8,
467^477.
[18] Deshpande, A.K. and Kung, H.F. (1987) Mol. Cell. Biol. 7,
1285^1288.
[19] Korn, L.J., Siebel, C.W., McCormick, F. and Roth, R.A. (1987)
Science 236, 840^843.
[20] Gibbs, J.B., Schaber, M.D., Scho¢eld, T.L. and Scolnick, E.M.
(1989) Proc. Natl. Acad. Sci. USA 86, 6630^6634.
[21] Chuang, L.M., Myers Jr., M.G., Backer, J.M., Shoelson, S.E.,
White, M.F., Birnbaum, M.J. and Kahn, C.R. (1993) Mol. Cell.
Biol. 13, 6653^6660.
[22] Muslin, A.J., Klippel, A. and Williams, L.T. (1993) Mol. Cell.
Biol. 13, 6661^6666.
[23] Katzav, S., Packham, G., Sutherland, M., Aroca, P., Santos, E.
and Cleveland, J. (1995) Oncogene 11, 1079^1088.
[24] Mahadevan, D., Thanki, N., Aroca, P., McPhie, P., Yu, J.C.,
Beeler, J., Santos, E., Wlodawer, A. and Heidaran, M. (1995)
Biochemistry 34, 2095^2106.
[25] Aroca, P., Bottaro, D.P., Ishibashi, T., Aaronson, S.A. and San-
tos, E. (1995) J. Biol. Chem. 270, 14229^14234.
[26] Font de Mora, J., Guerrero, C., Mahadevan, D., Coque, J.J.R.,
Rojas, J.M., Esteban, L.M., Rebecchi, M. and Santos, E. (1996)
J. Biol. Chem. 271, 18272^18277.
[27] Aroca, P., Mahadevan, D. and Santos, E. (1996) Oncogene 13,
1839^1846.
[28] Font de Mora, J., Uren, A., Heidaran, M. and Santos, E. (1997)
Oncogene 15, 2541^2553.
[29] Stephens, L.R., Jackson, T.R. and Hawkins, P.T. (1993) Bio-
chim. Biophys. Acta 1179, 27^75.
[30] Toker, A. and Cantley, L. (1997) Nature 387, 673^676.
[31] Vanhaesebroek, B., Leevers, S.J., Panayotou, G. and Water¢eld,
M. (1997) TIBS 22, 267^272.
[32] Franke, T.F., Kaplan, D.R. and Cantley, L.C. (1997) Cell 88,
435^437.
[33] Kotani, K., Yonezawa, K., Hara, K., Ueda, H., Kitamura, Y.,
Sakaue, H., Ando, A., Chavaneau, A., Calas, B. and Grigorescu,
F. et al. (1994) EMBO J. 13, 2313^2321.
[34] Wennstro«m, S., Hawkins, P., Cooke, F., Hara, K., Yonezawa,
K., Kasuga, M., Jackson, T., Claesson-Welsh, L. and Stephens,
L. (1994) Curr. Biol. 4, 385^393.
[35] Nobes, C.D., Hawkins, P., Stephens, L. and Hall, A. (1995)
J. Cell Sci. 108, 225^233.
[36] Rodriguez-Viciana, P., Warne, P.H., Vanhaesebroek, B., Water-
¢eld, M.D. and Downward, J. (1994) EMBO J. 15, 2442^2451.
[37] Klinghofer, R.A., Duckworth, B., Valius, M., Cantley, L. and
Kazlauskas, A. (1996) Mol. Cell. Biol. 16, 5905^5914.
[38] Rodriguez-Viciana, P., Warne, P.H., Khwaja, A., Marte, B.M.,
Pappin, D., Das, P., Water¢eld, M.D., Ridley, A. and Down-
ward, J. (1997) Cell 89, 457^467.
[39] Hu, Q., Klippel, A., Muslin, A.J., Fantl, W.J. and Williamns,
L.T. (1995) Science 268, 100^102.
[40] Gnudi, L., Frevert, E.U., Houseknetch, K.L., Erhart, P. and
Khan, B.B. (1997) Mol. Endocrinol. 11, 67^76.
[41] Kranenburg, O., Verlaan, I., Hordijk, P.L. and Moolenaar, W.H.
(1997) EMBO J. 16, 3097^3105.
[42] McIlroy, J., Chen, D., Wasow, C., Michaeli, T. and Backer, J.M.
(1997) Mol. Cell. Biol. 17, 248^255.
[43] Chuang, L.M., Hausdor¡, S.F., Myers Jr., M.G., White, M.F.,
Birnbaum, M.J. and Kahn, C.R. (1994) J. Biol. Chem. 269,
27645^27649.
[44] Liu, X.J., Sorisky, A., Zhu, L. and Pawson, T. (1995) Mol. Cell.
Biol. 15, 3563^3570.
[45] Yamamoto-Honda, R., Honda, Z., Ueki, K., Tobe, K., Kabu-
gari, Y., Takahashi, Y., Tamemoto, H., Suzuki, T., Itoh, K.,
Akanuma, Y., Yazaki, Y. and Kadowaki, T. (1996) J. Biol.
Chem. 271, 28677^28681.
[46] Andersen, C.B., Roth, R.A. and Conti, M. (1998) J. Biol. Chem.
273, 18705^18708.
[47] Deuter-Reinhard, M., Apell, G., Klippel, A., Williams, L.T. and
Kavanaugh, W.M. (1997) Mol. Cell. Biol. 17, 2559^2565.
[48] Gould, G.W., Jess, T.J., Andrews, G.C., Herbst, J.J., Plevin, R.J.
and Gibbs, E.M. (1994) J. Biol. Chem. 269, 26622^26625.
[49] Thomson, F.J., Moyes, C., Scott, P.H., Plevin, R. and Gould,
G.W. (1996) Biochem. J. 316, 161^166.
[50] Powis, G., Bonjoulian, R., Berggren, M.M., Gallegos, A., Abra-
ham, R., Ashendel, C., Zalkow, L., Matter, W.F., Dodge, J.,
Grindey, G. and Vlahos, C.J. (1949) Cancer Res. 54, 2419^2423.
[51] Vlahos, C.J., Matter, W.F., Hui, K.Y. and Brown, R.F. (1994)
J. Biol. Chem. 269, 5241^5248.
[52] Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. and Saltiel,
A.R. (1995) J. Biol. Chem. 270, 27489^27491.
[53] Billman, G.E. (1993) Am. J. Physiol. 265, H1529.
[54] Franke, T.F., Yang, S., Chang, T.O., Datta, K., Kazlaukas, A.,
Morrison, D.K., Kaplan, D.R. and Tsichlis, P.N. (1995) Cell 81,
727^736.
[55] Konishi, H., Matsuzaki, H., Tanaka, M., Ono, Y., Tokunaga,
C., Kuroda, S.I. and Kikkawa, U. (1996) Proc. Natl. Acad. Sci.
USA 93, 7639^7643.
[56] Alessi, D.R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice,
N., Cohen, O. and Hemmings, B.A. (1996) EMBO J. 15, 6541^
6551.
[57] Bravo, R., Otero, C., Allende, C.C. and Allende, J.E. (1978)
Proc. Natl. Acad. Sci USA 75, 1242^1246.
[58] Richter, J.D., Wasserman, W.J. and Smith, L.D. (1982) Dev.
Biol. 89, 159^167.
FEBS 22055 25-5-99
E. Lo¤pez-Herna¤ndez, E. Santos/FEBS Letters 451 (1999) 284^288288
